{
  "docId": "019de077-19d1-772e-933a-c7f1c42d9b04",
  "docSlug": "d223628377f56d072b5dbf426c21baf1",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 42,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a 'ribbon' style callout box on the right for the 'At a Glance' summary.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-19d1-772e-933a-c7f1c42d9b04/39",
  "deckHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04",
  "deckJsonHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04.json",
  "deckAnchorHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.38,
        "x": 0.58,
        "y": 0.42
      },
      "kind": "list",
      "text": "Target Product Profile:\nActive against HER2 and HER2ex20\nEGFR sparing: Related adverse events include skin rash and diarrhea\nBrain penetrant: ~19% of patients with HER2-positive NSCLC present with brain metastases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "670d76ad-9a61-4d6f-8875-6642e6129ac0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.58,
        "y": 0.14
      },
      "kind": "list",
      "text": "Mechanism of Action: HER2-selective tyrosine kinase inhibitor\nStage of Development: IND-enabling studies; Phase 1 initiation planned in 2024\nInitial Development Indication: HER2-positive NSCLC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac961436-13d8-4a32-9d73-c0ae2e7188ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.08,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "A brain-penetrant, HER2-selective inhibitor with activity against HER2 mutations and the potential to minimize EGFR-related adverse events",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "baf0245e-74a6-4e71-89ff-789d0d3982a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.08,
        "y": 0.46
      },
      "kind": "title",
      "text": "NVL-330 for HER2+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3924b2c9-94d7-4089-bd93-c2026905f057",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.65,
        "y": 0.06
      },
      "kind": "title",
      "text": "AT A GLANCE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "425b2560-56a4-4280-a998-e821d9690e61",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}